English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/189045
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Reactive oxygen comes of age: Mechanism-based therapy of diabetic end-organ damage

AuthorsElbatreek, Mahmoud H.; Pachado, Mayra P.; Cuadrado, Antonio ; Jandeleit-Dahm, Karin; Schmidt, Harald H.H.W.
KeywordsROS
NADPH oxidases
NRF2
Network pharmacology
Issue Date2019
PublisherElsevier
CitationTrends in Endocrinology and Metabolism 30(5): 312-327 (2019)
AbstractReactive oxygen species (ROS) have been mainly viewed as unwanted by-products of cellular metabolism, oxidative stress, a sign of a cellular redox imbalance, and potential disease mechanisms, such as in diabetes mellitus (DM). Antioxidant therapies, however, have failed to provide clinical benefit. This paradox can be explained by recent discoveries that ROS have mainly essential signaling and metabolic functions and evolutionally conserved physiological enzymatic sources. Disease can occur when ROS accumulate in nonphysiological concentrations, locations, or forms. By focusing on disease-relevant sources and targets of ROS, and leaving ROS physiology intact, precise therapeutic interventions are now possible and are entering clinical trials. Their outcomes are likely to profoundly change our concepts of ROS in DM and in medicine in general.
Publisher version (URL)https://doi.org/10.1016/j.tem.2019.02.006
URIhttp://hdl.handle.net/10261/189045
DOI10.1016/j.tem.2019.02.006
ISSN1043-2760
E-ISSN1879-3061
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
reactdamag.pdf2,33 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.